NeuroPace, Inc. (NPCE) Financial Statements
NeuroPace, Inc. (NPCE) reported trailing twelve-month revenue of $98.8M (up 11.6% year on year) and net income of -$19.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$11.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NPCENeuroPace, Inc.Follow NPCE — free
—
Price chart with a free account
- Market cap
- 443.1M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 45.2 | 45.5 | 65.4 | 79.9 | 100.0 | 98.8 | |
| Gross profit | 33.4 | 32.5 | 48.1 | 59.1 | 77.2 | 78.7 | |
| Research & development | 18.2 | 21.9 | 20.8 | 23.7 | 27.9 | 27.7 | |
| Operating income | -23.7 | -40.8 | -27.2 | -21.7 | -16.3 | -15.1 | |
| Pre-tax income | -36.1 | -47.1 | -33.0 | -27.1 | -21.5 | -19.1 | |
| Income tax | — | — | — | — | 0.0 | — | |
| Net income | -36.1 | -47.1 | -33.0 | -27.1 | -21.5 | -19.1 | |
| Diluted EPS ($) | -2.17 | -1.91 | -1.27 | -0.93 | -0.66 | -0.57 | |
| Diluted shares (mn) | 16.6 | 24.6 | 25.9 | 29.1 | 32.7 | — |
USD millions · SEC XBRL
NeuroPace, Inc. — questions
- What is NeuroPace, Inc.'s revenue?
- $98.8M over the twelve months to 2026-06-30, up 11.6% year on year, from its 10-Q and 10-K filings.
- What is NeuroPace, Inc.'s net income?
- -$19.1M over the twelve months to 2026-06-30.
- What is NeuroPace, Inc.'s free cash flow?
- -$11.6M over the twelve months to 2026-06-30.
- What are NeuroPace, Inc.'s diluted earnings per share?
- $-0.57 over the twelve months to 2026-06-30.
Every figure on this page comes from NeuroPace, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.